Phase 3 ROSELLA Trial Explores Relacorilant to Combat Chemoresistance in Ovarian Cancer
The ROSELLA trial is evaluating relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel for platinum-resistant ovarian cancer.
Corcept Completes Enrollment in Phase III Ovarian Cancer Study of Relacorilant
Corcept Therapeutics has completed enrollment in the Phase III ROSELLA study evaluating relacorilant plus Abraxane for recurrent, platinum-resistant ovarian cancer.
© Copyright 2025. All Rights Reserved by MedPath